Mergers and acquisitions – Page 17
-
BusinessRapid DNA sequencing cleared for the clinic
Illumina’s ‘next-generation’ MiSeqDx platform gets US approval
-
Business
Novartis sells off blood diagnostics division
$1.7bn deal reinforces firm’s focus on core pharmaceuticals
-
Business
Shire will cut UK R&D to focus on rare diseases
$4.2bn buyout of ViroPharma bolsters pipeline, while Basingstoke site halts research
-
Business
Solvay expands surfactants business with Chemlogics buyout
$1.3bn deal brings firm into booming US oil and gas drilling market
-
Business
Aspen acquires anticoagulant brands
South African drugmaker buys thrombosis drugs from GSK for £700m
-
Business
Clariant expands into China
Firm buys pigments arm of Jiangsu Multicolor and will build new plant
-
Business
Algal oil producer steps up supply
Solazyme to provide 10,000 tonnes of tailored oil to Unilever
-
Business
Nanobody inflammation drug attracts Abbvie
$840m licensing deal shows support for antibody fragments
-
Business
GSK divests Lucozade and Ribena brands
£1.35 billion deal allows GSK to focus on pharma business
-
Business
Otsuka to buy Astex for $886 million
Japanese firm intends to leave Astex’s fragment-based R&D efforts intact
-
Business
Amgen snaps up Onyx in huge biotech deal
$10.4 billion acquisition will expand firm’s oncology portfolio
-
Business
Endo Health to buy Boca Pharmacal for $225m
Endo agrees to buy generics firm Boca as two major patents expire
-
Business
J&J buys Aragon’s prostate cancer arm
Hormone cancer specialist spins out other programmes before sale
-
BusinessAkzoNobel sells building adhesives unit for €260m
Sika will take on two manufacturing sites and 550 employees
-
BusinessPfizer reshuffle hints at future split decision
Could pharma giant’s ‘value’ and ‘innovative’ segments get broken apart?
-
Business
Perrigo bags Elan and its bargain Irish tax rates
$8.6bn deal ends Elan’s takeover battle with Royalty Pharma
-
Business
Thousands face job cuts after Valeant's Bausch buyout
Valeant plans to shed 10-15% of its workforce to save $800 million
-
Business
Aspen in $1 billion deal with Merck & Co
South African generics manufacturer to buy 11 drug brands and an API business from the US drugmaker